<?xml version="1.0" encoding="utf8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">JSLR</journal-id>
      <journal-title-group>
        <journal-title>Journal of Spleen And Liver Research</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2578-2371</issn>
      <publisher>
        <publisher-name>Open Access Pub</publisher-name>
        <publisher-loc>United States</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">JSLR-23-4446</article-id>
      <article-id pub-id-type="doi">10.14302/issn.2578-2371.jslr-23-4446</article-id>
      <article-categories>
        <subj-group>
          <subject>research-article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Magnitude and Trends of Chronic Liver Disease:      A Retrospective Hospital Based Study in Eastern Amhara Region, Northeast Ethiopia </article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Minwuyelet</surname>
            <given-names>Maru Temesgen</given-names>
          </name>
          <xref ref-type="aff" rid="idm1839940132">1</xref>
          <xref ref-type="aff" rid="idm1839939772">2</xref>
          <xref ref-type="aff" rid="idm1840030076">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Seid</surname>
            <given-names>Legesse Hassen</given-names>
          </name>
          <xref ref-type="aff" rid="idm1839940132">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Birtukan</surname>
            <given-names>Shiferaw Ayalew</given-names>
          </name>
          <xref ref-type="aff" rid="idm1839940132">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Anteneh</surname>
            <given-names>Demelash Abate</given-names>
          </name>
          <xref ref-type="aff" rid="idm1839940132">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nega</surname>
            <given-names>Berhe Belay</given-names>
          </name>
          <xref ref-type="aff" rid="idm1839939772">2</xref>
        </contrib>
      </contrib-group>
      <aff id="idm1839940132">
        <label>1</label>
        <addr-line>Amhara Public Health Institute Dessie Branch, P.O.Box 686, Dessie, Amhara Region, Ethiopia</addr-line>
      </aff>
      <aff id="idm1839939772">
        <label>2</label>
        <addr-line>Addis Ababa University, Aklilu Lemma Institute of Pathobiology, Addis Ababa, Ethiopia </addr-line>
      </aff>
      <aff id="idm1840030076">
        <label/>
        <addr-line>*Corresponding author</addr-line>
      </aff>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Sevgi</surname>
            <given-names>Ciftci</given-names>
          </name>
          <xref ref-type="aff" rid="idm1839785812">1</xref>
        </contrib>
      </contrib-group>
      <aff id="idm1839785812">
        <label>1</label>
        <addr-line>Istanbul University</addr-line>
      </aff>
      <author-notes>
        <corresp>Corresponding author: Minwuyelet Maru Temesgen, Amhara Public Health Institute, Dessie Branch, P.O. Box 686, Dessie, Amhara Region, Ethiopia. Email: <email>minwuyelet@yahoo.com</email></corresp>
        <fn fn-type="conflict" id="idm1840647124">
          <p>The authors have declared that no competing interests exist.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub" iso-8601-date="2023-06-22">
        <day>22</day>
        <month>06</month>
        <year>2023</year>
      </pub-date>
      <volume>1</volume>
      <issue>4</issue>
      <fpage>8</fpage>
      <lpage>16</lpage>
      <history>
        <date date-type="received">
          <day>23</day>
          <month>01</month>
          <year>2023</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>05</month>
          <year>2023</year>
        </date>
        <date date-type="online">
          <day>22</day>
          <month>06</month>
          <year>2023</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© </copyright-statement>
        <copyright-year>2023</copyright-year>
        <copyright-holder>Minwuyelet Maru Temesgen, et al</copyright-holder>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://openaccesspub.org/jslr/article/1972">This article is available from http://openaccesspub.org/jslr/article/1972</self-uri>
      <abstract>
        <p>A retrospective study quantifies chronic liver disease burden and trends in Eastern Amhara. It summarizes demographics, etiologies, and outcomes to inform regional planning.</p>
      </abstract>
      <kwd-group>
        <kwd>liver</kwd>
        <kwd>Non-alcoholic Fatty Liver Disease</kwd>
        <kwd>chronic liver disease </kwd>
      </kwd-group>
      <counts>
        <fig-count count="1"/>
        <table-count count="3"/>
        <page-count count="9"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="idm1839785020" sec-type="intro">
      <title>Introduction</title>
      <p>There are many different types of liver diseases and conditions that affect liver function. These can be acute liver failure, which results in a rapid loss of liver function usually within days or weeks, and chronic liver disease, which is characterized by a gradual deterioration of liver functions which could progress to cirrhosis or to hepatocellular carcinoma (HCC) <xref ref-type="bibr" rid="ridm1841202668">1</xref>. Cirrhosis caused an estimated 1.32 million deaths in 2017, with 80 to 90% of patients progressing to HCC which is the fifth most common cancer in the world and the second leading cause of cancer death in men, trailing only lung cancer <xref ref-type="bibr" rid="ridm1841197340">2</xref>. Various etiologies of chronic liver diseases have been reported, with the most common being Alcoholic Liver Disease, Non-alcoholic Fatty Liver Disease (NAFLD) or nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction- associated fatty liver disease (MAFLD), and chronic hepatitis B and C infections. Drugs, genetic causes, autoimmune diseases, and unexplained causes are also stated <xref ref-type="bibr" rid="ridm1841197340">2</xref>.</p>
      <p>Alcohol-related liver disease accounts for 9.5% of CLD worldwide, with rates varying by region, with Europe having the highest rates <xref ref-type="bibr" rid="ridm1841207644">3</xref>. Metabolic dysfunction-associated fatty liver disease is also the most common type of chronic liver disease, affecting more than 1 billion people worldwide, with prevalence ranging from 6% to 35%, with the highest rates in developed countries <xref ref-type="bibr" rid="ridm1841274100">4</xref>. However, MAFLD is frequently asymptomatic or patients may experience non-specific symptoms and it is underestimated in developing countries due to screening and diagnosis practices<xref ref-type="bibr" rid="ridm1841202668">1</xref><xref ref-type="bibr" rid="ridm1841058604">5</xref>. Viral hepatitis is the second leading etiology of CLD in developing countries with hepatitis B and C being among the most common. It is estimated that 10% of acute HBV infections and 80% of acute HCV cases progress to chronic disease <xref ref-type="bibr" rid="ridm1841056084">6</xref>. Globally, more than 257 million people were living with chronic HBV in 2021, with 20% expected to die prematurely from liver failure or hepatocellular carcinoma. It was estimated that only 11% of infected people were aware of their infection, with only 17% receiving treatment which could be much higher in developing countries <xref ref-type="bibr" rid="ridm1841062708">7</xref>.</p>
      <p>Every year, approximately 2 million CLD deaths occur as a result of cirrhosis, viral hepatitis, and HCC complications and the prevalence of cirrhosis ranged 4.5% to 9.5% <xref ref-type="bibr" rid="ridm1841050372">8</xref>. According to a global study of liver disease, mortality from cirrhosis increased by 47.15%, with the temporal trend varying depending on the etiology <xref ref-type="bibr" rid="ridm1841045332">9</xref>.</p>
      <p> The global trend showed epidemiology shift of CLD, an increasing metabolic and alcoholic liver disease, and a decreasing hepatitis viruses<xref ref-type="bibr" rid="ridm1841052172">10</xref>. According to findings decreasing trend of overall CLD death rate in all age groups was driven by the decrease in the proportion of people with HBV but the death rate for HCV and NAFLD was increased<xref ref-type="bibr" rid="ridm1841036124">11</xref>. However, pattern varies by country, and viral hepatitis remains the leading cause of CLD in in sub-Saharan Africa. Countries also take different approaches to prevention and treatment, as well as access to health care <xref ref-type="bibr" rid="ridm1841041668">12</xref><xref ref-type="bibr" rid="ridm1841032828">13</xref>.</p>
      <p>In Ethiopia, CLD was the 7th leading cause of death in 2019 and according to studies the three most common etiologies were Hepatitis B virus, alcohol, and hepatitis C virus with a prevalence of 40%, 17% and 15% respectively which showed variation by gender and age <xref ref-type="bibr" rid="ridm1841029444">14</xref><xref ref-type="bibr" rid="ridm1841023900">15</xref><xref ref-type="bibr" rid="ridm1841022820">16</xref>. A significant proportion of NAFLD was also reported which is likely underreported given the rising prevalence of non-communicable diseases, such as type 2 diabetes and obesity as studies revealed high proportion of NAFLD among type 2 diabetic patients in different parts of the country <xref ref-type="bibr" rid="ridm1841020660">17</xref><xref ref-type="bibr" rid="ridm1840997332">18</xref>. Furthermore, data about CLD, demographic and socio-economic factors in the study area is scarce <xref ref-type="bibr" rid="ridm1840994020">19</xref><xref ref-type="bibr" rid="ridm1840992652">20</xref>. Therefore, this study aimed to describe the types and trend of CLD in the eastern Amhara region of North east Ethiopia</p>
    </sec>
    <sec id="idm1839782500" sec-type="methods">
      <title>Methods</title>
      <sec id="idm1839782788">
        <title>Study design and Settings</title>
        <p>A retrospective hospital-based study was conducted in Dessie comprehensive specialized hospital, Amhara region, Ethiopia from January, 2018 to December, 2022 to estimate the magnitude, by etiologies and temporal trend of chronic liver disease. The hospital is serving as referral site for an estimated 10 million people.</p>
      </sec>
      <sec id="idm1839783076">
        <title>Inclusion and exclusion criteria</title>
        <p>Data was collected from patients with liver disease and those visiting the hospital from 2018 to 2022 was included and others were excluded.</p>
      </sec>
      <sec id="idm1839790276">
        <title>Data collection</title>
        <p>Data collector nurses were trained from the hospital and pretested data abstraction checklist was used to abstract data from the medical records.</p>
      </sec>
      <sec id="idm1839788116">
        <title> Ethical Approval</title>
        <p>Ethical approval was obtained from the Amhara Public Health Institute Dessie Branch ethics review committee (ID: APHI_DB/RTTD/17/2015) and permission to conduct the study was granted from relevant authorities</p>
        <p>
          <italic>Data Analysis</italic>
        </p>
        <p>Data was entered into Epi Info v7 and exported to STATA 14 for analysis. Frequencies, Proportions and summary statistics were used to describe the subjects in relation to the studied variables; the results are presented with tables.</p>
      </sec>
    </sec>
    <sec id="idm1839789700" sec-type="results">
      <title>Results</title>
      <p>A total of 89 medical records of liver patients were observed of which the majority 59 (66.3%) were males and 66 (74.2%) rural residents. The median age was 35 years ranged 4 to 85 (SD± 15.7) and about half (48.3%) were below 35 years age (<xref ref-type="table" rid="idm1841512412">Table 1</xref>).</p>
      <table-wrap id="idm1841512412">
        <label>Table 1.</label>
        <caption>
          <title>Socio-demographic characteristics of CLD among patients in Dessie comprehensive specialized hospital, Amhara region, North east Ethiopia, from January, 2018 to December,2022.</title>
        </caption>
        <table rules="all" frame="box">
          <tbody>
            <tr>
              <th>
                <bold>Characteristics</bold>
              </th>
              <td>
                <bold>Frequency</bold>
              </td>
              <td>
                <bold>Percent</bold>
              </td>
            </tr>
            <tr>
              <td>
                <bold>Gender</bold>
              </td>
              <td>
                <bold> </bold>
              </td>
              <td> </td>
            </tr>
            <tr>
              <td>Male</td>
              <td>59</td>
              <td>66.3</td>
            </tr>
            <tr>
              <td>Female</td>
              <td>30</td>
              <td>33.7</td>
            </tr>
            <tr>
              <td>
                <bold>Residence</bold>
              </td>
              <td>
                <bold> </bold>
              </td>
              <td> </td>
            </tr>
            <tr>
              <td>Rural</td>
              <td>66</td>
              <td>74.2</td>
            </tr>
            <tr>
              <td>Urban</td>
              <td>23</td>
              <td>25.8</td>
            </tr>
            <tr>
              <td>
                <bold>Age group</bold>
              </td>
              <td>
                <bold> </bold>
              </td>
              <td> </td>
            </tr>
            <tr>
              <td>&lt;18 years</td>
              <td>5</td>
              <td>5.6</td>
            </tr>
            <tr>
              <td>18 – 24 years</td>
              <td>8</td>
              <td>9</td>
            </tr>
            <tr>
              <td>25 – 34 Years</td>
              <td>30</td>
              <td>33.7</td>
            </tr>
            <tr>
              <td>35 – 44 Years</td>
              <td>15</td>
              <td>16.9</td>
            </tr>
            <tr>
              <td>45 – 54 years</td>
              <td>12</td>
              <td>13.5</td>
            </tr>
            <tr>
              <td>&gt;55 years</td>
              <td>19</td>
              <td>21.3</td>
            </tr>
            <tr>
              <td>
                <bold>Total</bold>
              </td>
              <td>89</td>
              <td>100</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>The most common clinical presentation was ascites which accounted 68.5% followed by jaundice (19.1%). The mean duration of clinical sign was 6.5 months with minimum of 1 a maximum of 36 months. Hypertension was seen as frequently observed comorbidity at proportion of 11.2% followed by diabetes and tuberculosis at 4.5%. Twenty seven study participants (30.3%) were anemic and 21 (23.6%) had history of taking drug for long time (<xref ref-type="table" rid="idm1841434428">Table 2</xref>).</p>
      <table-wrap id="idm1841434428">
        <label>Table 2.</label>
        <caption>
          <title>Clinical Patterns of chronic liver disease patients in Dessie comprehensive specialized hospitals, Amhara region, North east Ethiopia, from January, 2018 to December, 2022</title>
        </caption>
        <table rules="all" frame="box">
          <tbody>
            <tr>
              <th>
                <bold>Characteristics</bold>
              </th>
              <td>
                <bold>Frequency</bold>
              </td>
              <td>
                <bold>Percent</bold>
              </td>
            </tr>
            <tr>
              <td>Clinical presentation</td>
              <td> </td>
              <td> </td>
            </tr>
            <tr>
              <td>Ascites</td>
              <td>61</td>
              <td>68.5</td>
            </tr>
            <tr>
              <td>Jaundice</td>
              <td>17</td>
              <td>19.1</td>
            </tr>
            <tr>
              <td>Bloody vomit</td>
              <td>9</td>
              <td>10.1</td>
            </tr>
            <tr>
              <td>Mental sign</td>
              <td>1</td>
              <td>1.1</td>
            </tr>
            <tr>
              <td>Other</td>
              <td>1</td>
              <td>1.1</td>
            </tr>
            <tr>
              <td>
                <bold>CLD Type</bold>
              </td>
              <td>
                <bold> </bold>
              </td>
              <td> </td>
            </tr>
            <tr>
              <td>Alcoholic Liver Disease</td>
              <td>19</td>
              <td>21.3</td>
            </tr>
            <tr>
              <td>Nonalcoholic Faty Liver Disease</td>
              <td>16</td>
              <td>18</td>
            </tr>
            <tr>
              <td>Chronic Hepatitis B infection</td>
              <td>29</td>
              <td>32.6</td>
            </tr>
            <tr>
              <td>Chronic Hepatitis C infection</td>
              <td>3</td>
              <td>3.4</td>
            </tr>
            <tr>
              <td>Hepatosplinic schistosomiasis</td>
              <td>6</td>
              <td>6.7</td>
            </tr>
            <tr>
              <td>Unexplained</td>
              <td>16</td>
              <td>18</td>
            </tr>
            <tr>
              <td>
                <bold>Comorbidity</bold>
              </td>
              <td>
                <bold> </bold>
              </td>
              <td> </td>
            </tr>
            <tr>
              <td>No</td>
              <td>68</td>
              <td>76.4</td>
            </tr>
            <tr>
              <td>Diabetes</td>
              <td>4</td>
              <td>4.5</td>
            </tr>
            <tr>
              <td>Hypertension</td>
              <td>10</td>
              <td>11.2</td>
            </tr>
            <tr>
              <td>Tuberculosis</td>
              <td>4</td>
              <td>4.5</td>
            </tr>
            <tr>
              <td>Diabetes and Hypertension</td>
              <td>1</td>
              <td>1.1</td>
            </tr>
            <tr>
              <td>Other</td>
              <td>1</td>
              <td>2.2</td>
            </tr>
            <tr>
              <td>
                <bold>Anemia</bold>
              </td>
              <td>
                <bold> </bold>
              </td>
              <td> </td>
            </tr>
            <tr>
              <td>Yes</td>
              <td>27</td>
              <td>30.3</td>
            </tr>
            <tr>
              <td>No</td>
              <td>62</td>
              <td>69.7</td>
            </tr>
            <tr>
              <th>
                <bold>Long time taken drug</bold>
              </th>
              <td>
                <bold> </bold>
              </td>
              <td>
                <bold> </bold>
              </td>
            </tr>
            <tr>
              <td>Yes</td>
              <td>21</td>
              <td>23.6</td>
            </tr>
            <tr>
              <td>No</td>
              <td>68</td>
              <td>76.4</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Chronic hepatitis B infection was the most frequent etiology of CLD at 32.6% followed by Alcoholic liver disease and Nonalcoholic fatty liver disease at 21.3% and 18% respectively. In sixteen (18%) study subjects, unexplained cause of CLD was seen with 21 (23.6%) subjects with long time drug intake was identified most frequently for hypertension (11.2%), and diabetes (4.5%). Majority of CLD cases are males 59 (66.3%) and the most frequent etiology in males is chronic hepatitis B infection and alcoholic liver disease whereas, non-alcoholic liver disease and hepatitis B virus cause are the main etiology in females. As indicated in <xref ref-type="table" rid="idm1841354508">table 3</xref>, alcoholic and nonalcoholic liver disease is largely prevalent among age group above 55 years old and chronic hepatitis B infection is high in the age group 19-24 years. About three-fourth of CLD is prevalent among rural residents and all chronic Hepatitis B infection, Alcoholic liver disease, Non-alcoholic liver disease and unexplained causes of CLD are most frequent among rural than urban.</p>
      <table-wrap id="idm1841354508">
        <label>Table 3.</label>
        <caption>
          <title>Distribution of chronic liver disease etiology in Dessie comprehensive specialized hospitals of Amhara region, Northeast Ethiopia, from January, 2018 to December, 2022 </title>
        </caption>
        <table rules="all" frame="box">
          <tbody>
            <tr>
              <th>
                <bold>Characteristics</bold>
              </th>
              <td>
                <bold>ALD</bold>
              </td>
              <td>
                <bold>NALD</bold>
              </td>
              <td>
                <bold>HBV</bold>
              </td>
              <td>
                <bold>HCV</bold>
              </td>
              <td>
                <bold>Schistosomiasis</bold>
              </td>
              <td>
                <bold>Unexplained</bold>
              </td>
              <td>
                <bold>Total (%)</bold>
              </td>
            </tr>
            <tr>
              <td>
                <bold>Gender</bold>
              </td>
              <td>
                <bold> </bold>
              </td>
              <td> </td>
              <td> </td>
              <td> </td>
              <td> </td>
              <td> </td>
              <td> </td>
            </tr>
            <tr>
              <td>Male</td>
              <td>14</td>
              <td>6</td>
              <td>22</td>
              <td>3</td>
              <td>4</td>
              <td>10</td>
              <td>59 (66.3%)</td>
            </tr>
            <tr>
              <td>Female</td>
              <td>5</td>
              <td>10</td>
              <td>7</td>
              <td>0</td>
              <td>2</td>
              <td>6</td>
              <td>30 (33.7%)</td>
            </tr>
            <tr>
              <td>
                <bold>Age in years</bold>
              </td>
              <td>
                <bold> </bold>
              </td>
              <td> </td>
              <td> </td>
              <td> </td>
              <td> </td>
              <td> </td>
              <td> </td>
            </tr>
            <tr>
              <td>Below 18</td>
              <td>0</td>
              <td>0</td>
              <td>2</td>
              <td>0</td>
              <td>1</td>
              <td>2</td>
              <td>5 (5.6%)</td>
            </tr>
            <tr>
              <td>19-24</td>
              <td>0</td>
              <td>0</td>
              <td>7</td>
              <td>0</td>
              <td>1</td>
              <td>0</td>
              <td>8 (9.0%)</td>
            </tr>
            <tr>
              <td>25-34</td>
              <td>2</td>
              <td>4</td>
              <td>10</td>
              <td>2</td>
              <td>3</td>
              <td>9</td>
              <td>30 (33.7%)</td>
            </tr>
            <tr>
              <td>35-44</td>
              <td>4</td>
              <td>5</td>
              <td>3</td>
              <td>1</td>
              <td>1</td>
              <td>1</td>
              <td>15 (16.9%)</td>
            </tr>
            <tr>
              <td>45-54</td>
              <td>4</td>
              <td>1</td>
              <td>5</td>
              <td>0</td>
              <td>0</td>
              <td>2</td>
              <td>12 (13.5%)</td>
            </tr>
            <tr>
              <td>55 and above</td>
              <td>9</td>
              <td>6</td>
              <td>2</td>
              <td>0</td>
              <td>0</td>
              <td>2</td>
              <td>19 (21.3%)</td>
            </tr>
            <tr>
              <td>
                <bold>Residence</bold>
              </td>
              <td>
                <bold> </bold>
              </td>
              <td> </td>
              <td> </td>
              <td> </td>
              <td> </td>
              <td> </td>
              <td> </td>
            </tr>
            <tr>
              <td>Urban</td>
              <td>4</td>
              <td>4</td>
              <td>10</td>
              <td>0</td>
              <td>0</td>
              <td>5</td>
              <td>23 (25.8%)</td>
            </tr>
            <tr>
              <td>Rural</td>
              <td>15</td>
              <td>12</td>
              <td>19</td>
              <td>3</td>
              <td>6</td>
              <td>11</td>
              <td>66 (74.2%)</td>
            </tr>
            <tr>
              <td>
                <bold>Total</bold>
              </td>
              <td>19</td>
              <td>16</td>
              <td>29</td>
              <td>3</td>
              <td>6</td>
              <td>16</td>
              <td>89 (100%)</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>In our study, aspartate transaminase (AST) and alanine transaminase (ALT) enzyme measurement was detected in 69 study subjects and increased level was observed for AST in 32 (46.3%) and for ALT in 19 subjects (27.5%) and for both in 17 (24.6%) based on ALT and AST reference limit of 0-42U/L and 0-37 U/L currently used in the country respectively. High level of AST than ALT which is mostly related to cirrhosis was observed in 49 (71.0%) study participants.</p>
      <p>As shown in the graph below, the five year trend of CLD types in the study area exhibit variation in proportion and rate of increment (<xref ref-type="fig" rid="idm1841245132">Figure 1</xref>). It is noticed that all types of CLD increase from 2018 to 2021 and chronic hepatitis B is the most contributing cause with highest rate of increment while hepatitis C virus infection and hepatosplenic schistosomiasis were among the least. In 2021 and onwards, alcoholic liver disease remain stable contrary to nonalcoholic liver disease which show upward trend.</p>
      <fig id="idm1841245132">
        <label>Figure 1.</label>
        <caption>
          <title> Five year trend of CLD types </title>
        </caption>
        <graphic xlink:href="images/image1.jpg" mime-subtype="jpg"/>
      </fig>
    </sec>
    <sec id="idm1839645612" sec-type="discussion">
      <title>Discussion</title>
      <p>Chronic liver disease is believed to be distributed in different population groups and geographic area and this retrospective hospital based study was done to determine the five year magnitude and trends of chronic liver disease and describes the different types of CLD. In our finding, it was noted that CLD was most frequently distributed among males, age group below 35 years and rural residents. A study from Addis Ababa, Ethiopia also reported high prevalence of CLD in males than females. However, it contrasts to the Addis Ababa finding that showed the most commonly affected age group of 31 to 50 years <xref ref-type="bibr" rid="ridm1840990780">21</xref>. This could be due to the fact that there might be epidemiologic difference between rural and urban setting in terms of factors causing liver disease. Secondly, in our study rural residents are included in the study and alcoholic liver disease is the second most frequent cause of CLD highly prevalent among age group above 55 years old whereas, in the Addis Ababa study alcoholic liver disease was the leading factor which is attributable to old age.</p>
      <p>The most frequent etiology of CLD in the present study was chronic hepatitis B infection (32.6%), Alcoholic liver disease (21.35) and Nonalcoholic fatty liver disease (18%). This finding reveals hepatitis B infection remains the leading cause of CLD in Ethiopia similar to previous reports in Sub-Sahara Africa at 34%. Likewise, alcohol is the second cause of CLD which contributed slightly higher than previous 18% of CLD in Sub Sahara Africa. On the other hand, the proportion of NAFLD in this study is higher than the previous report of 12% in Ethiopia<xref ref-type="bibr" rid="ridm1841020660">17</xref> and 13.5% in African countries. However, the global proportion of NAFLD is about 25% and due to change in lifestyle and increasing comorbidities particularly diabetes and obesity the finding is still underestimated <xref ref-type="bibr" rid="ridm1840986172">22</xref>. In addition, unexplained causes of CLD was reported in a significantly higher proportion (18%) of study subjects. Although it is lower than previous finding of 45% in the country<xref ref-type="bibr" rid="ridm1841020660">17</xref>, it might be related to unexplained factors such as long time taken drugs, Khat chewing or rare genetic conditions which are missed due to poor diagnosis.</p>
      <p>This study found that, NAFLD and hepatitis B are the most common causes of chronic liver disease in females at 33.3% (10 out of 30) and 23.3% (7 out of 30) respectively unlike in males where hepatitis B and alcohol are the most common etiologies of CLD at 37.3% (22 out of 59) and 10.1% (6 out of 59) respectively. This shows sign of epidemiology change to NAFLD in the adult population similar to the global trend <xref ref-type="bibr" rid="ridm1840999996">23</xref>. Furthermore, chronic hepatitis B infection is the causative factor of almost all 87.5% (7 out of 8) chronic liver disease in the age group 19-24 years which might indicate the presence of past high rate of mother to child transmission before the launch of national childhood hepatitis vaccination programs <xref ref-type="bibr" rid="ridm1840976060">24</xref> or increased risk of sexual acquisition in the younger population as various reported similar findings which require additional preventive measures <xref ref-type="bibr" rid="ridm1840970948">25</xref>.</p>
      <p>Ascites is the main signs of liver cirrhosis resulted from portal hypertension and it is the most frequently seen clinical presentation in the present study at 68.5% which higher than previous report of 46.2% from Gondar, Ethiopia <xref ref-type="bibr" rid="ridm1841022820">16</xref>. But as compared to findings from developed countries where ascites, accounting about 80% of case, it is much lower that might be due prevalence variation across different geographic regions <xref ref-type="bibr" rid="ridm1840968284">26</xref>. However, the mean health facility visit of 6.5 months after clinical sign was observed in our study which is indicative of delay in early screening and treatment until advanced stage of the disease is reached that influence its management and outcome.</p>
      <p>Aminotransferase enzymes, aspartate aminotransferase (AST) and alanine aminotransferase (ALT), are commonly associated with liver disease as both enzymes are highly concentrated in the liver. However, as AST is also spread to the heart, skeletal muscle, kidneys, brain and red blood cells, an increase in ALT is more specific for liver damage including sign of nonalcoholic fatty liver disease <xref ref-type="bibr" rid="ridm1840966916">27</xref>. Various studies also showed AST to ALT ratio of greater than 1 suggests cirrhosis <xref ref-type="bibr" rid="ridm1840960580">28</xref>. Nonetheless, AST and ALT can vary according to age, sex, comorbidity conditions, or medication intake and chronic hepatitis and cirrhotic patients may have aminotransferase levels within the reference range. In our finding, increased level of AST and ALT is observed in 46.3% and 27.5% respectively with increment of both enzymes in 24.6% and 49 (71.0%) study participants had AST to ALT ratio of greater than one which reveals about two third of chronic liver patients in the study area were in the advanced cirrhotic stage which is higher than reports from Africa <xref ref-type="bibr" rid="ridm1840948356">29</xref>.</p>
      <p>Increasing five year trend of all forms of CLD is also observed in this study with hepatitis infection remaining the highest and still showed increasing trend. On top of this nonalcoholic fatty liver disease and unexplained causes of chronic liver disease are linearly increasing which reveals the importance of addressing metabolic disorders and improving the diagnosis of liver disease.</p>
    </sec>
    <sec id="idm1839645900" sec-type="conclusions">
      <title>Conclusions</title>
      <p>In conclusion, this study showed the most frequent etiology of CLD in the study area is hepatitis B infection, Alcohol and Nonalcoholic fatty liver disease. The proportion of NAFLD and unexplained causes of CLD are higher than the previous reports and increasing five year trend of all forms of CLD is also observed. In this finding chronic liver disease is most frequently distributed among males, age group below 35 years and rural residents. Non-alcoholic fatty liver disease and hepatitis B are the most common causes of chronic liver disease in females whereas, hepatitis B infection is the major causative factor chronic liver disease in the age group 19-24 years and current interventions should consider this population groups. About two third of chronic liver patients in the study area were in the advanced cirrhotic stage indicated by ascites and AST to ALT ratio of greater than one which reveals delay in diagnosis suggesting the need of early screening.</p>
    </sec>
    <sec id="idm1839647124">
      <title>Source of Funding</title>
      <p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
    </sec>
    <sec id="idm1839645324">
      <title>Declaration on interest</title>
      <p>The author(s) declared no conflicts of interest in preparing this article.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>The authors would like to thank data collectors and medical record officers for their effort to collect the data</p>
    </ack>
    <ref-list>
      <ref id="ridm1841202668">
        <label>1.</label>
        <mixed-citation xlink:type="simple" publication-type="book"><chapter-title>StatPearls. 2022 Treasure Island (FL:</chapter-title>
Sharma A and N. S., Chronic Liver Disease. , ed
<publisher-name>StatPearls Publishing</publisher-name></mixed-citation>
      </ref>
      <ref id="ridm1841197340">
        <label>2.</label>
        <mixed-citation xlink:type="simple" publication-type="journal"><name><surname>Asafo-Agyei</surname><given-names>K O</given-names></name><name><surname>Carcinoma</surname><given-names>S H Hepatocellular</given-names></name><date><year>2022</year></date>
Sep/2022]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK559177/



</mixed-citation>
      </ref>
      <ref id="ridm1841207644">
        <label>3.</label>
        <mixed-citation xlink:type="simple" publication-type="journal"><name><surname>W</surname><given-names>G Organisation</given-names></name><article-title>Global Burden of Liver Diseases: A true burden on Health</article-title><date><year>2020</year></date>
Available from: https://www.worldgastroenterology.org/publications



</mixed-citation>
      </ref>
      <ref id="ridm1841274100">
        <label>4.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Liu</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults. Clinical Gastroenterology and Hepatology</article-title>
          <date>
            <year>2022</year>
          </date>
          <volume>20</volume>
          <issue>3</issue>
          <fpage>573</fpage>
          <lpage>582</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841058604">
        <label>5.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Yamamura</surname>
            <given-names>Sakura</given-names>
          </name>
          <article-title>Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis</article-title>
          <date>
            <year>2020</year>
          </date>
          <source>Journal of Gastroenterology</source>
          <volume>36</volume>
          <issue>3</issue>
          <fpage>629</fpage>
          <lpage>636</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841056084">
        <label>6.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>McKeating</surname>
            <given-names>C</given-names>
          </name>
          <article-title>Progression from acute to chronic hepatitis B is more common in older adults. Ulster Med J</article-title>
          <date>
            <year>2018</year>
          </date>
          <volume>87</volume>
          <issue>3</issue>
          <fpage>177</fpage>
          <lpage>180</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841062708">
        <label>7.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Cheemerla</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Balakrishnan</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Global Epidemiology of Chronic Liver Disease. Clin Liver Dis (Hoboken)</article-title>
          <date>
            <year>2021</year>
          </date>
          <volume>17</volume>
          <issue>5</issue>
          <fpage>365</fpage>
          <lpage>370</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841050372">
        <label>8.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>S</surname>
            <given-names>K Asrani</given-names>
          </name>
          <article-title>Burden of liver diseases in the world</article-title>
          <source>Journal of hepatology</source>
          <volume>70</volume>
          <issue>1</issue>
          <fpage>151</fpage>
          <lpage>171</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841045332">
        <label>9.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Cheemerla</surname>
            <given-names>Shantan</given-names>
          </name>
          <name>
            <surname>Balakrishnan</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Global Epidemiology of Chronic Liver Disease. CLD Clinical Liver Disease, A Multimidia Review Journal</article-title>
          <date>
            <year>2021</year>
          </date>
          <volume>17</volume>
          <issue>5</issue>
          <fpage>365</fpage>
          <lpage>370</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841052172">
        <label>10.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>A</surname>
            <given-names>M Moon</given-names>
          </name>
          <name>
            <surname>A</surname>
            <given-names>G Singal</given-names>
          </name>
          <name>
            <surname>E</surname>
            <given-names>B Tapper</given-names>
          </name>
          <article-title>Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clinical Gastroenterology and Hepatology</article-title>
          <date>
            <year>2020</year>
          </date>
          <volume>18</volume>
          <issue>12</issue>
          <fpage>2650</fpage>
          <lpage>2666</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841036124">
        <label>11.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>J</surname>
            <given-names>M Paik</given-names>
          </name>
          <article-title>Global burden of NAFLD and chronic liver disease among adolescents and young adults. Hepatology</article-title>
          <date>
            <year>2022</year>
          </date>
          <volume>75</volume>
          <issue>5</issue>
          <fpage>1204</fpage>
          <lpage>1217</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841041668">
        <label>12.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Ye</surname>
            <given-names>F</given-names>
          </name>
          <article-title>The burden of liver cirrhosis in mortality: Results from the global burden of disease study. Frontiers in Public Health</article-title>
          <date>
            <year>2022</year>
          </date>
          <fpage>10</fpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841032828">
        <label>13.</label>
        <mixed-citation xlink:type="simple" publication-type="book">
          <name>
            <surname>N</surname>
            <given-names>G Ladep</given-names>
          </name>
          <name>
            <surname>Akbar</surname>
            <given-names>S M F</given-names>
          </name>
          <name>
            <surname>Mahtab</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Global Epidemiology of Chronic Liver Disease</article-title>
          <date>
            <year>2019</year>
          </date>
          <chapter-title>in Clinical Epidemiology of Chronic Liver Diseases, R.J. Wong</chapter-title>
          <fpage>41</fpage>
          <lpage>55</lpage>
          <publisher-name>Springer International Publishing: Cham</publisher-name>
        </mixed-citation>
      </ref>
      <ref id="ridm1841029444">
        <label>14.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>GBD</surname>
            <given-names/>
          </name>
          <article-title>The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study</article-title>
          <date>
            <year>2017</year>
          </date>
          <volume>5</volume>
          <issue>3</issue>
          <fpage>245</fpage>
          <lpage>266</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841023900">
        <label>15.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Tesfaye</surname>
            <given-names>Terefe</given-names>
          </name>
          <name>
            <surname>B</surname>
            <given-names/>
          </name>
          <article-title>Short-term clinical outcomes of patients admitted with chronic liver disease to selected teaching hospitals in Ethiopia. PloS one</article-title>
          <date>
            <year>2019</year>
          </date>
          <volume>14</volume>
          <issue>8</issue>
          <fpage>0221806</fpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841022820">
        <label>16.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>O</surname>
            <given-names>A Muhie</given-names>
          </name>
          <article-title>Causes and clinical profiles of ascites at University of Gondar Hospital, Northwest Ethiopia: institution-based cross-sectional study</article-title>
          <date>
            <year>2019</year>
          </date>
          <source>Canadian Journal of Gastroenterology and Hepatology</source>
        </mixed-citation>
      </ref>
      <ref id="ridm1841020660">
        <label>17.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>B</surname>
            <given-names>T Tesfaye</given-names>
          </name>
          <article-title>Chronic liver disease in Ethiopia with a particular focus on the etiological spectrums: a systematic review and meta-analysis of Observational Studies. Canadian Journal of Gastroenterology and Hepatology</article-title>
          <date>
            <year>2021</year>
          </date>
        </mixed-citation>
      </ref>
      <ref id="ridm1840997332">
        <label>18.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Zawdie</surname>
            <given-names>B</given-names>
          </name>
          <article-title>Non-alcoholic fatty liver disease and associated factors among type 2 diabetic patients in Southwest Ethiopia</article-title>
          <date>
            <year/>
          </date>
          <source>Ethiopian Journal of Health Sciences</source>
          <volume>28</volume>
          <issue>1</issue>
          <fpage>p.</fpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1840994020">
        <label>19.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Orlien</surname>
            <given-names>S M S</given-names>
          </name>
          <article-title>Khat chewing increases the risk for developing chronic liver disease: A hospital‐based case–control study. Hepatology</article-title>
          <date>
            <year>2018</year>
          </date>
          <volume>68</volume>
          <issue>1</issue>
          <fpage>248</fpage>
          <lpage>257</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1840992652">
        <label>20.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Orlien</surname>
            <given-names>S M S</given-names>
          </name>
          <article-title>Unexplained chronic liver disease in Ethiopia: a cross-sectional study. BMC gastroenterology</article-title>
          <date>
            <year>2018</year>
          </date>
          <volume>18</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>12</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1840990780">
        <label>21.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Samson</surname>
            <given-names>E</given-names>
          </name>
          <article-title>Liver Disease: A Retrospective Hospital Based Study in Addis Ababa-</article-title>
          <source>Ethiopia. Journal of Spleen And Liver Research</source>
          <volume>1</volume>
          <issue>4</issue>
          <fpage>1</fpage>
          <lpage>7</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1840986172">
        <label>22.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>C</surname>
            <given-names>W Spearman</given-names>
          </name>
          <article-title>Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa. The Lancet Gastroenterology &amp; Hepatology</article-title>
          <date>
            <year>2021</year>
          </date>
          <volume>6</volume>
          <issue>12</issue>
          <fpage>1036</fpage>
          <lpage>1046</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1840999996">
        <label>23.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Stefan</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Häring</surname>
            <given-names>H-U</given-names>
          </name>
          <name>
            <surname>Cusi</surname>
            <given-names>K</given-names>
          </name>
          <article-title>Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. The Lancet Diabetes &amp; Endocrinology</article-title>
          <date>
            <year>2019</year>
          </date>
          <volume>7</volume>
          <issue>4</issue>
          <fpage>313</fpage>
          <lpage>324</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1840976060">
        <label>24.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>M</surname>
            <given-names>E Hamida</given-names>
          </name>
          <article-title>Prevalence of chronic hepatitis B phases in Eritrean patients: a laboratory-based cross-sectional study. BMC Gastroenterol</article-title>
          <date>
            <year>2021</year>
          </date>
          <volume>21</volume>
          <issue>1</issue>
          <fpage>198</fpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1840970948">
        <label>25.</label>
        <mixed-citation xlink:type="simple" publication-type="journal"><name><surname>Li</surname><given-names>J</given-names></name><article-title>The Changing Epidemiology of Liver Disease Among US Children and Adolescents From</article-title><date><year>1999</year></date><volume>116</volume><issue>10</issue><fpage>2068</fpage><lpage>2078</lpage>
to



</mixed-citation>
      </ref>
      <ref id="ridm1840968284">
        <label>26.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Tufoni</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Zaccherini</surname>
            <given-names>G</given-names>
          </name>
          <article-title>Albumin: Indications in chronic liver disease</article-title>
          <date>
            <year>2020</year>
          </date>
          <volume>8</volume>
          <issue>5</issue>
          <fpage>528</fpage>
          <lpage>535</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1840966916">
        <label>27.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>W</surname>
            <given-names>R Kim</given-names>
          </name>
          <article-title>Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology</article-title>
          <date>
            <year>2008</year>
          </date>
          <volume>47</volume>
          <issue>4</issue>
          <fpage>1363</fpage>
          <lpage>1370</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1840960580">
        <label>28.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>NYBLOM</surname>
            <given-names>H</given-names>
          </name>
          <date>
            <year>2004</year>
          </date>
          <source>HIGH AST/ALT RATIO MAY INDICATE ADVANCED ALCOHOLIC LIVER DISEASE RATHER THAN HEAVY DRINKING. Alcohol and Alcoholism</source>
          <volume>39</volume>
          <issue>4</issue>
          <fpage>336</fpage>
          <lpage>339</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1840948356">
        <label>29.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>O&amp;apos;Hara</surname>
            <given-names>G</given-names>
          </name>
          <article-title>Liver function tests and fibrosis scores in a rural population in Africa: a cross-sectional study to estimate the burden of disease and associated risk factors. BMJ Open</article-title>
          <date>
            <year>2020</year>
          </date>
          <volume>10</volume>
          <issue>3</issue>
          <fpage>032890</fpage>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
